Discontinued — last reported Q4 '21
Global Interventional Cardiology Ic Reporting Unit — Net Sales
Boston Scientific Global Interventional Cardiology Ic Reporting Unit — Net Sales increased by 8.6% to $808.00M in Q4 2021 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing demand for the company's cardiac intervention products and successful market adoption of new technologies, while a decrease may signal increased competition, pricing pressure, or a slowdown in elective cardiovascular procedures.
Detailed definition
This metric represents the total revenue generated from the sale of medical devices and technologies specifically design...
Peer comparison
Comparable to interventional cardiology revenue segments reported by major medical device competitors like Abbott Laboratories, Medtronic, and Edwards Lifesciences.
bsx_segment_global_interventional_cardiology_ic_reporting_unit_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | |
|---|---|---|---|
| Value | $790.00M | $744.00M | $808.00M |
| QoQ Change | — | -5.8% | +8.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's global interventional cardiology ic reporting unit — net sales?
- Boston Scientific (BSX) reported global interventional cardiology ic reporting unit — net sales of $808.00M in Q4 2021.
- What does global interventional cardiology ic reporting unit — net sales mean?
- The total revenue earned from selling medical devices used in heart-related, minimally invasive procedures.